HOYA Vision Care has announced new clinical evidence from three key clinical studies highlighting the impact of Defocus Incorporated Multiple Segments (DIMS) technology.
The results were presented as part of the company’s 2025 scientific program, Exploring New Frontiers in Myopia Management with MiYOSMART, at the Association for Research in Vision and Ophthalmology (ARVO) 2025 annual meeting in Salt Lake City, Utah, US.
HOYA said the latest findings from the world’s longest-running clinical study on myopia management spectacle lenses showed that continuous DIMS spectacle lens wear demonstrated significantly reduced myopia progression (-1.00D ± 0.41D, p=0.017) and axial elongation (0.42 ± 0.18 mm, p=0.019) consistently for the full eight years (n=11) of follow-up.1
This evidence demonstrates that wearing MiYOSMART spectacle lenses continuously and for the long-term may improve myopia management outcomes, the company said.
Dr Natalia Vlasak, global head of medical and scientific affairs at HOYA Vision Care, said: “This landmark study, featuring the longest follow-up to date for myopia management spectacle lenses, reveals that long-term MiYOSMART use continues to significantly slow myopia progression so that children can enjoy their lives to the fullest.
“These findings emphasise the life-changing value of long-term adherence, providing crucial information and guidance for eyecare professionals and parents committed to protecting children’s vision health for the future.”
The first 12-month data readout from the ASPECT randomised controlled trial demonstrated that combining low-dose 0.025% atropine eye drops with DIMS spectacle lenses stopped myopia progression in around 40% of children.2
The mean change in axial length, a key factor in myopia progression, was significantly lower than in the atropine-only group (0.07 ± 0.16 mm vs 0.18 ± 0.16 mm; p<0.001). The researchers also explored vision-related quality of life (VR-QoL), indicating a trend towards improvement in general vision (p=0.049) and competence (p=0.031) in children using low-dose atropine and DIMS spectacle lens combination treatment.
“Our findings suggest that combining MiYOSMART spectacle lenses with atropine can unlock even greater outcomes for children with myopia progression, marking a positive step towards more personalised, powerful treatment strategies in myopia management that suit the unique needs of each child,” said Dr Vlasak.
A first-of-its-kind pilot study evaluating DIMS spectacle lenses for pre-myopia management in five and six-year-old children indicated that the DIMS technology may offer a protective effect against the development of myopia in this population, said HOYA.
Over nine months, the average cycloplegic spherical equivalent refraction (SER) remained stable with a yearly change of +0.06D compared with -0.15D in a control group.
While axial length increased slightly (22.48 mm to 22.64 mm, p<0.01), the choroidal thickness remained stable.
The company said these promising initial findings suggest MiYOSMART spectacle lenses may help to prevent myopia development and postpone the myopia onset in pre-myopic preschoolers, laying the groundwork for future research.3
Those keen to know more on the abstracts presented at ARVO 2025, can visit https://www.hoyavision.com/visionary-knowlegde/blogs-and-article/conference-arvo-2025/.
References
1.Leung TW, et al. Comparison of Myopia Progression in Individuals Wearing Defocus Incorporated Multiple Segments (DIMS) Spectacle Lenses for Eight Years versus Shorter Durations. Poster number A0113. Presented 6th May, ARVO 2025.
2. Guemes-Villahoz N, et al. Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine. Poster number B0466 . Presented 7th May, ARVO 2025.
3. Yang HY, Tsai DC. Efficacy of Defocus Incorporated Multiple Segments (DIMS) Lenses in Retarding Myopic Shifts Among Pre-Myopic Preschoolers: Nine-Month Results of a Pilot Study. Poster number A0104. Presented 7th May, ARVO 2025.
4. Garcia EH, et al. Vision-related quality of life in myopic children using combination treatment with atropine and DIMS (Defocus Incorporated Multiple Segments) spectacle lenses: 12-month results. Poster number A0297. Presented 5th May, ARVO 2025.
More reading
New HOYA coating cuts UV transmission through Sensity lenses
50 years of HOYA . . . and still evolving
HOYA Digital Fitting among latest technologies supporting independents
